Drug intelligence / Profile preview

HPDC-T cells + interferon alfa-2a

Development stage: Preclinical
Modality: Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous, Intramuscular

Overview

This is a combination therapy approach that utilizes HPDC-T cells (Human Peripheral Dendritic Cells-derived T cells) together with interferon alfa-2a. Interferon alfa-2a is a type I interferon that binds to interferon receptors (IFNAR1 and IFNAR2c), activating Janus kinase tyrosines (Jak1 and Tyk2) which then phosphorylate themselves and the receptors. This leads to binding of Stat1 and Stat2, which dimerize and activate multiple immunomodulatory and antiviral proteins. The therapy appears to be investigated for treatment of various cancers, particularly cutaneous T-cell lymphoma, where interferon alfa-2a has shown efficacy in combination treatments.

Other names: HPDC-T cells + IFN-a-2a

Targets

JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on HPDC-T cells + interferon alfa-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPDC-T cells + interferon alfa-2a.

Explore the full profile